ClinicalTrials.gg
RecruitingNCT07158970Updated Jul 2, 2026

Home-Ultrasound in Routine High-Risk Care of Patients With Gestational Diabetes Mellitus (GDM)

An interventional study of Use of the Pulsenmore home ultrasound device for fetal assessment, guided remotely by a physician. in Gestational Diabetes Mellitus, sponsored by Wolfson Medical Center. Recruiting at 1 site in Israel. Open to female participants aged 18 Years to 51 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Wolfson Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 51 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Diabetes, Gestational with a site in Israel — 6 open to participants now, 6 under way, none of them phase 3. Diabetes, Gestational · Israel.

Planned enrollment
15th of 15
90 · median 142
Started
2026
the only one that year
No phase
13 of 25
5 open now
Registered
25th of 25
by date
Lead sponsor
2 of 25
Wolfson Medical Center

Among the 25 studies in Diabetes, Gestational with a site in Israel, this one is the 15th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 13 with no phase, and was the 25th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

6 of the 25 studies in Diabetes, Gestational with a site in Israel are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 51 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Diabetes, Gestational with a site in Israel, or all of them as a file.
02

Study summary

This study evaluates the impact of incorporating home-ultrasound (home-US) devices into telemedicine care for patients with gestational diabetes mellitus (GDM). The study will compare satisfaction, clinical outcomes, and healthcare costs between standard high-risk pregnancy care and care augmented by home-US.

Read the detailed description

Gestational diabetes mellitus (GDM) requires frequent follow-up to monitor maternal and fetal well-being. While telemedicine improves access and patient satisfaction, it lacks a fetal assessment component. This single-center randomized controlled trial evaluates the integration of home ultrasound (home-US) into telemedicine care for women with GDM.

Participants will be randomized to standard care or an intervention group receiving alternating in-person and telemedicine visits with physician-guided home-US using the Pulsenmore device. The primary outcome is patient satisfaction measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at term. Secondary outcomes include glycemic control, maternal and neonatal outcomes, healthcare utilization, visit duration, and follow-up costs.

The study will enroll 90 women, aged 18-51, with singleton pregnancies and GDM. The study is conducted at the Edith Wolfson Medical Center in Israel over a one-year period. The home-US device is approved for obstetric use and will be used under real-time physician supervision.

03

Conditions studied

  • Gestational Diabetes Mellitus

Browse trials for

Keywords

  • home ultrasound
  • telemedicine
04

Who can participate

Ages eligible
18 Years to 51 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Singleton pregnancy
  • GDM diagnosed by OGTT or glucose monitoring
  • Hebrew speaking
  • Compatible cellphone

Exclusion criteria

Exclusion Criteria:

  • Pregestational diabetes
  • Fetal anomalies/genetic abnormalities
  • Multifetal pregnancy
  • Late GDM diagnosis (after 34 weeks)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Home-US Group

    Home Ultrasound Monitoring

    Device: Use of the Pulsenmore home ultrasound device for fetal assessment, guided remotely by a physician.

  • No intervention
    Standard Care Group

    Standard high-risk follow up in clinic

Interventions

  • DeviceUse of the Pulsenmore home ultrasound device for fetal assessment, guided remotely by a physician.

    Standard care

06

What researchers measure

Primary outcomes

  1. Patient satisfaction

    Assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ). It is composed of eight questions, each of which is scored by patients on a scale ranging from zero ("very dissatisfied", "very inconvenient") to six (e.g., "very satisfied", "very convenient"). The questionnaire is composed of two different factors- the first 6 questions assess treatment satisfaction and the last 2 questions assess burden of hyper or hypo-glycemia. the sum of the first 6 points (maximum 36 points) score the treatment satisfaction, with a higher score indicating higher treatment satisfaction.

    Time frame: at 37-39 weeks gestation

Secondary outcomes

  1. Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score

    Difference in patient satisfaction as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ) between early pregnancy (after first visit) and late pregnancy (37-39 weeks gestation). It is composed of eight questions, each of which is scored by patients on a scale ranging from zero ("very dissatisfied", "very inconvenient") to six (e.g., "very satisfied", "very convenient"). The questionnaire is composed of two different factors- the first 6 questions assess treatment satisfaction and the last 2 questions assess burden of hyper or hypo-glycemia. the sum of the first 6 points (maximum 36 points) score the treatment satisfaction, with a higher score indicating higher treatment satisfaction.

    Time frame: From enrollment (~24-28 weeks) to 37-39 weeks gestation.

  2. Glycemic Control

    Assessment of maternal glycemic control based on percent of abnormal glucose values during follow-up (via glucose log or continuous glucose monitoring where available), as recorded by treating physician.

    Time frame: From enrollment to delivery.

  3. Clinician Satisfaction

    Clinician satisfaction will be assessed using a structured questionnaire developed for this study. Physicians will rate various aspects of the telemedicine or in-person follow-up experience, including: Ease of use Clinical value Workflow and efficiency Communication and patient engagement Technical issues and support Each domain will be rated on a 10-point numeric rating scale (0-10), where: 0 = Not satisfied at all 10 = Extremely satisfied Higher scores indicate greater satisfaction.

    Time frame: At the end of study participation for each patient (between 37-39 weeks gestation).

  4. Mode of Delivery

    Evaluation of mode of delivery (vaginal, cesarean)

    Time frame: At time of delivery.

  5. Neonatal birth-weight

    Birth weight

    Time frame: At time of delivery

  6. Estimated Patient Follow-up Costs

    Estimated costs incurred by patients for follow-up (including travel, parking, time off work), collected via structured questionnaire.

    Time frame: At 37-39 weeks gestation.

  7. Estimated Institutional Follow-up Costs

    Estimated resource and time costs for the healthcare system based on visit type (in-person vs. telemedicine), calculated per patient.

    Time frame: From enrollment to delivery.

  8. Visit Duration

    Duration of each visit, separately recorded for patient time and physician Duration of each clinical visit will be recorded in minutes for both the patient and the physician. This includes both in-person and telemedicine encounters. Separate timing will be documented for: Patient time (including waiting and consultation) Physician time (active interaction and documentation) These data will be used to compare time efficiency between the two care models.

    Time frame: Through study completion, an average of 1 year (from enrollment to delivery for each participant)

  9. Unscheduled Emergency Department Visits

    Number and reason for unscheduled emergency room visits related to pregnancy or GDM during the study period.

    Time frame: From enrollment to 6 weeks postpartum, confirmed by patient interview and EMR.

  10. Gestational age at birth

    Gestational age at birth

    Time frame: collected after birth from data system

  11. Number of Neonates Admitted to the Neonatal Intensive Care Unit (NICU)

    The number of neonates requiring admission to the neonatal intensive care unit (NICU) following delivery will be recorded and reported. This will be used as an indicator of neonatal morbidity.

    Time frame: Within the first 28 days of life

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.

Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 17 months is below that.

Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Sep 8, 2025
StartActual
Mar 1, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Nov 1, 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07158970
Collaborators
PulseNmore
Responsible party
Liat Mor (OBGYN resident, Wolfson Medical Center) — Principal investigator
First posted
Sep 8, 2025
Start date
Mar 1, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Liat Mor
Contact
liatmor1@gmail.com
+972546738294
Michal De-Wolf
Contact
michald@wmc.gov.il
03-5028346
LIat Mor
principal investigator · Edith Wolfson Medical center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion